

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Kowalik MA, Puliga E, Cabras L, Sulas P, Petrelli A, Perra A, et al. (2020). Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. JOURNAL OF HEPATOLOGY, 72(6), 1159-1169 [10.1016/j.jhep.2019.12.018].

Availability:

This version is available at: <https://hdl.handle.net/11585/850911> since: 2022-02-21

Published:

DOI: <http://doi.org/10.1016/j.jhep.2019.12.018>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

This is the final peer-reviewed accepted manuscript of:

Kowalik MA, Puliga E, Cabras L, Sulas P, Petrelli A, Perra A, et al. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. Journal of Hepatology 2020;72:1159–69.
<https://doi.org/10.1016/j.jhep.2019.12.018>.

The final published version is available online at:

<https://doi.org/10.1016/j.jhep.2019.12.018>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>)

When citing, please refer to the published version.

Thyroid hormone inhibits hepatocellular carcinoma progression *via* induction of differentiation and metabolic reprogramming

Marta Anna Kowalik^{1*}, Elisabetta Puliga^{1,8*}, Lavinia Cabras^{1*}, Pia Sulas¹, Annalisa Petrelli², Andrea Perra¹, Giovanna Maria Ledda-Columbano¹, Andrea Morandi³, Simone Merlin⁴, Claudia Orrù^{1,8}, Carlos Sanchez-Martin⁶, Francesca Fornari⁵, Laura Gramantieri⁵, Matteo Parri³, Andrea Rasola⁶, Sara Erika Bellomo², Carlos Sebastian², Antonia Follenzi⁴, Silvia Giordano^{2,7§} and Amedeo Columbano^{1§}.

¹Department of Biomedical Sciences, School of Medicine, University of Cagliari, Italy; ²Candiolo Cancer Institute -FPO,IRCCS, Candiolo, Italy; ³Department of Experimental and Clinical Biomedical Sciences, University of Florence, Italy; ⁴Department of Health Sciences, University of Piemonte Orientale, Novara, Italy; ⁵CRBA Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi, 40138, Bologna, Italy; ⁶Department of Biomedical Sciences, University of Padova, Italy; ⁷Department of Oncology, University of Turin, Italy.

⁸Present address: Candiolo Cancer Institute – FPO, IRCCS, Candiolo, Italy.

*These authors equally contributed to the work

§ to whom correspondence should be addressed.

Short Title: T3 impairs HCC progression

Key words: T3, Thyroid hormone receptors, HCC, rats, differentiation, metabolic reprogramming, KLF9, PPP, OXPHOS.

Correspondence:

Amedeo Columbano, PhD
Department of Biomedical Sciences
Unit of Oncology and Molecular Pathology
University of Cagliari
Cittadella Universitaria, SP. 8 Monserrato
09042 Monserrato
Phone: +39-070-6758345
e-mail: columbano@unica.it

Silvia Giordano MD, PhD
Department of Oncology
University of Torino, Medical school
Candiolo Cancer Institute – FPO, IRCCS Strada Provinciale 142
Candiolo (Torino), 10060, Italy
Phone + 39 0119933233
Fax +39 011 9933225
e-mail silvia.giordano@unito.it

Abbreviations: 2-AAF: 2-acetylaminofluorene; ATPase: adenosine triphosphatase; Cas-3: caspase 3; ChIP: chromatin immunoprecipitation; CMD: choline-devoid methionine-deficient; DAB: 3,3'-diaminobenzidine; DAPI: 4',6-diamidino-2-phenylindole; DENA: diethylnitrosamine; DIO1: deiodinase 1; G6Pase: glucose-6-phosphatase; G6PD: glucose-6-phosphate dehydrogenase; GCK: glucokinase; GGT: gamma glutamyl transpeptidase; GLUT1: glucose transporter 1; GST-P: placental form of glutathione-S-transferase; HCC: hepatocellular carcinoma; HK2: hexokinase 2; HNF: Hepatocyte Nuclear Factor; IPA: Ingenuity Pathway Analysis; KLF9: Kruppel-like factor 9; KRT-19: cytokeratin-19; LMD: Laser-capture microdissection; MCT4: monocarboxylate transporter 4; OXPHOS: oxidative phosphorylation; NQO1: NAD(P)H Quinone Dehydrogenase 1; PCK1: phosphoenolpyruvate carboxykinase 1; PDK1: pyruvate dehydrogenase kinase 1; PEP: phosphoenolpyruvate; PGC-1a: peroxisome proliferator-activated receptor gamma coactivator 1 alpha; PGK1: phosphoglycerate kinase 1; PPP: pentose phosphate pathway; qPCR: quantitative-PCR; R5P: ribose 5-phosphate; R-H: Resistant-Hepatocyte; SDH: succinate dehydrogenase; T3: 3,5,3'-triiodo-L-thyronine; T4: 3,5,3',5'-tetraiodo-L-thyronine; TALDO1: transaldolase 1; TH: thyroid hormone; TKT: transketolase; TR: thyroid hormone receptor.

Financial support

This work was supported by Associazione Italiana Ricerca sul Cancro (AIRC, Grants IG-20176 to AC; IG 20210 to SG; IG-20749 to AR, AIRC and Fondazione Cassa di Risparmio di Firenze 19515 to AM); Fondazione Banco di Sardegna to AC and AP. MAK is a recipient of Fondazione Umberto Veronesi fellowship. The work of AM was funded by Associazione Italiana Ricerca sul Cancro and Fondazione Cassa di Risparmio di Firenze (Multiuser program - grant 19515).

Conflict of interest statements

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest concerning this manuscript. Please refer to the accompanying ICMJE disclosure forms for further details.

Authors' contributions

MAK, LC, EP, CO; performed the in vivo experiments and analyzed data. **APet, EP**; performed in vitro experiments. **SM, AF**; performed the mouse experiment with inoculated hepatoma cells; **LG, FF**; provided human HCC and analyzed data. **PS**; performed bioinformatics and data analysis. **APer, GMLC**; performed in vivo experiments, histopathologic classification and contributed to the study design. **AR, CSM**; performed studies on the activity of G6PD and mitochondrial Complex I and Complex II. **PS**; performed bioinformatics analyses. **AM**; performed the radioactive assay. **MP**; performed the metabolomics assay; **CS, SEB**; performed ChIP assay; **AC, SG**; conceived and supervised the study, provided funding, wrote the manuscript.

Abstract word count: 256; Word count: 6727; Total number of figures: 8

ABSTRACT

Background & Aims: The limited therapeutic options available for hepatocellular carcinoma (HCC) make mandatory to find alternative effective treatments for this tumor. Based on the recent finding that systemic or local hypothyroidism is associated with HCC development in humans and rodents, we investigated whether the thyroid hormone triiodothyronine (T3) could inhibit the progression of hepatocellular carcinomas (HCCs).

Methods: Different rat and mouse models of hepatocarcinogenesis were investigated. The effect of T3 on tumorigenesis and metabolism/differentiation was evaluated by transcriptomic analysis, quantitative-PCR, immunohistochemistry, and enzymatic assay.

Results: A short treatment with T3 caused a shift of global expression profile of the most aggressive preneoplastic nodules towards that of normal liver. This genomic reprogramming preceded the disappearance of nodules and involved reprogramming of metabolic genes as well as pro-differentiating transcription factors, including Kruppel-like factor 9 (Klf9), a target of the thyroid hormone receptor β (TR β). Treatment of HCCs-bearing rats with T3 strongly reduced the number and burden of HCCs. Reactivation of a local T3/TR β axis, switch from Warburg to oxidative metabolism and loss of markers of poorly differentiated hepatocytes accompanied HCC reduction. This effect persisted one month after T3 withdrawal suggesting a long-lasting effect of the hormone. The antitumorigenic effect of T3 was further supported by its inhibitory activity on cell growth and tumorigenic ability of human HCC cell lines.

Conclusions: Collectively, these findings suggest that re-activation of the T3/TR β axis induces differentiation of neoplastic cells towards a more benign phenotype and that T3 or its analogues, particularly agonists of the TR β , can represent useful tools in HCC therapy.

Lay Summary

Hepatocellular carcinoma (HCC) represents an important challenge for global health. Recent findings showed that systemic or local hypothyroidism is associated with HCC development. In rat models, we showed that T3 administration impaired HCC progression, even when given at late stages, most likely by prompting a differentiation program and a metabolic switch. This is relevant from a translational point of view as HCC is often diagnosed at an advanced stage when it is no longer amenable to curative treatments. Thyroid hormone and/or thyromimetics could improve the prognosis of HCC patients.

INTRODUCTION

Hepatocellular carcinoma (HCC), the third most common cause of cancer mortality worldwide¹, represents an important challenge for global health. Despite an important raise in incidence, current therapeutic options for HCC remain unsatisfactory².

Thyroid hormones (THs), namely 3,5,3'-triiodo-L-thyronine (T3) and 3,5,3',5'-tetraiodo-L-thyronine (thyroxine or T4), influence a variety of physiological processes, including development, metabolism, cell growth and proliferation^{3,4}. Although it has been proposed that rapid non-genomic mechanisms initiated at the cell membrane could mediate thyroid hormones activity⁵, most of the effects of THs on cellular proliferation and differentiation are driven by the thyroid hormone nuclear receptors (TRs) TR α and TR β ^{3,4}. Liver is an important target organ of THs where TR β represents the most abundant isoform⁶.

In the last years, growing evidence has demonstrated that THs and TRs are implicated in HCC development. Indeed, two case-control studies suggested that hypothyroidism represents a risk factor for HCC^{7,8}. In the first study, Hassan *et al.* observed an increased association between hypothyroidism and HCC in women, independent of established HCC risk factors; in the second one, hypothyroidism was significantly more prevalent in HCC patients with an unknown etiology. In addition, a recent work showed that TR β expression correlated with more progressed stages of non-alcoholic steatohepatitis (NASH), a pro-tumorigenic condition⁹. These results suggest that hypothyroidism may represent a permissive factor for HCC development.

In addition, a status of severe local hypothyroidism, revealed by down-regulation of TR β and *Dio1* mRNA levels has been identified in the most aggressive rat hepatic preneoplastic lesions, characterized by their positivity for the stem/progenitor cell marker cytokeratin-19 (KRT-19)¹⁰, and in rat and human HCCs^{11,12}. Finally, the finding that an increased expression of these genes upon T3 treatment was associated with preneoplastic

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

nodule regression¹⁰ suggests that local reactivation of the T3/TR axis in cancer cells may impact on HCC development.

Based on these premises, we investigated whether reactivation of the T3/TR axis in fully developed HCCs could impact on their progression, even when the hormone is administered at late phases. This is relevant, as HCC is often diagnosed at an advanced stage when it is not amenable to curative treatments. Collectively, our findings show that T3 acts as a potent anti-tumoral agent, most likely by prompting a differentiation program and a metabolic switch.

Materials and Methods

Animals and treatments. Male Fischer and Wistar rats (75-100g) and CD1 nude mice were obtained from Charles River (Milano, Italy). Guidelines for Care and Use of Laboratory Animals were followed during the investigation. All animal procedures were approved by the Ethical Commission of the University of Cagliari and the Italian Ministry of Health.

Six experimental protocols were used for the study of rat hepatocarcinogenesis. CD-1 experiments were performed as described¹³. For details see Supplementary Material and Figures S1-3.

Histology, Immunohistochemistry, Enzyme histochemistry and Immunofluorescence. Liver sections were fixed in 10% formalin or snap-frozen in liquid nitrogen. For details see Supplementary Material.

Laser-capture micro-dissection. Nodules positive for both the placental form of Glutathione S-transferase (GSTP) and KRT-19 or for GSTP alone were identified by immunohistochemistry (IHC) of 6-µm-thick frozen liver sections. Nodule microdissection was performed on 16-µm serial sections with a Leica LMD6000 (Leica Microsystems), as previously described¹⁴. Equivalent areas of normal livers were similarly microdissected.

mRNA Expression Profiling. Total RNA was extracted from 8/10 preneoplastic nodules (obtained from 3/4 animals) with the MirVana kit, and from HCCs with TRIzol (Thermo Fisher Scientific). For the gene expression profile, 150 ng of RNA were amplified (Illumina TotalPrep RNA Amplification Kit), labeled and hybridized on Illumina microarray (RatRef-12 V1 BeadChips, Illumina Inc.), including 21.791 genes. Gene array data are available at GEO, accession number GSE131034 mRNAs validation was performed using specific TaqMan assays (Life Technologies). For further details and data analysis, see Supplementary Material.

Chromatin immunoprecipitation (ChIP) assays. ChIP assays were performed as previously described¹⁵ with some modifications. For details see Supplementary Material.

Gas chromatography-MS (GC-MS) was performed as described in Supplementary Material.

Cell cultures and in vitro experiments. Human HepG2 and Mahlavu cell lines were cultured as described in Supplementary Material. Cell transduction, growth and soft-agar assays were performed as described in Supplementary Material.

Enzymatic activity measurement of the respiratory chain Complex I and II and G6PD, and Radioactive assay. Liver tissues from HCC bearing-rats with or without T3 treatment were frozen in liquid nitrogen-cooled isopentane and cut in 16µm-thick sections. For each sample 50 mg of liver tissue were homogenized in different buffers depending on the assay. For details see Supplementary Material.

Patients. The cohort consisted of HCC and cirrhotic tissues obtained from 45 randomly selected patients (33 males and 12 females, median age \pm SD: 69.3 \pm 4.9) undergoing resection for HCC at the Department of Surgery of the University of Bologna. The characteristics of patients are described in **Supplementary Table 1**. For further details, see Supplementary Material.

Statistics. Data are expressed as mean \pm either standard deviation (SD) or standard error (SE). Analysis of significance was done by either Student's *t*-test or Mann-Whitney and by One-Way ANOVA using the GraphPad software (La Jolla, California).

RESULTS

T3 induces a global shift of the expression profile of preneoplastic lesions towards that of fully differentiated hepatocytes

Using the R-H model of hepatocarcinogenesis (see Material and Methods) we previously showed that a 7-day treatment with T3 to rats bearing hepatic nodules induced a rapid regression of these preneoplastic lesions, in the absence of clear signs of cell death¹⁵. To investigate the molecular mechanisms underlying the observed regression, we performed a transcriptomic analysis of laser-microdissected preneoplastic nodules at 2 and 4 days after T3 treatment, times that precede the disappearance of the nodules. A total of 869 out of 21,791 genes included in the array were selected as described in Supplementary Material. Unsupervised hierarchical cluster analysis stratified the rat lesions of T3-untreated animals into two major clusters: 1) normal liver and preneoplastic lesions negative for KRT-19; 2) the most aggressive preneoplastic KRT-19+ lesions¹⁴. T3 administration for 4 days induced a shift in the gene expression profile of KRT-19+ lesions towards that of normal liver and indolent preneoplastic KRT-19- lesions (as evidenced by unsupervised co-clustering). Conversely, no major gene expression profile changes were observed after 2 days of treatment (**Fig. 1A**). These results suggest that the T3-induced reprogramming of poorly differentiated hepatocytes to a more mature phenotype precedes the disappearance of preneoplastic lesions. Indeed, the ratio between the most aggressive and poorly differentiated KRT-19+ nodules and those KRT-19- before and after T3 treatment was 0.33 and 0.14, respectively. According to our previous findings¹⁶, nodule

1 regression was not associated to increased apoptosis compared to untreated rats, as
2 revealed by histology and immunohistochemical detection of activated caspase-3 (data not
3 shown).
4
5
6
7
8

9 ***T3 treatment modulates pathways and transcription factors related to the***
10 ***acquisition/maintenance of a differentiated phenotype.***
11

12 Ingenuity Pathway Analysis (IPA) of the genes differentially expressed in KRT-19+
13 preneoplastic lesions after 4 days of T3 treatment vs. untreated lesions, revealed their
14 involvement in metabolic pathways, such as those related to lipopolysaccharide
15 (LPS)/interleukin (IL)-1-mediated inhibition of retinoic-X-receptor (RXR) function, NRF2-
16 mediated oxidative response and glutathione-mediated detoxification (**Fig. 1B**).
17 Remarkably, T3 treatment caused activation of Hepatocyte Nuclear Factor 1-alpha
18 (*Hnf1a*), Hepatocyte Nuclear Factor 4-alpha (*Hnf4a*) and CCAAT Enhancer Binding
19 Protein alpha (*Cebpa*), involved in the acquisition/maintenance of the differentiated
20 hepatocyte phenotype¹⁷ (**Fig. 1C**). Among the T3-activated transcription factors, it was of
21 particular interest to find *Klf9*, a Kruppel-like factor that contains a thyroid hormone
22 response element and is implicated in the regulation of the balance between pluripotency,
23 self-renewal differentiation, and metabolism¹⁸⁻²⁰ (**Fig. S4**). Of note, some of the most
24 deregulated genes resulted to be direct targets of TR β or *Klf9*, as shown by ChIP analysis
25 (**Fig. S5**).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 To further investigate the pro-differentiating effect of T3, we determined the expression of
49 genes involved in hepatocyte differentiation. As previously shown¹⁰, hepatic preneoplastic
50 nodules are characterized by a local hypothyroid state. qPCR analysis showed that T3
51 treatment reverted this status, as revealed by the strong induction of the TR β -target gene
52 Deiodinase 1 (*Dio1*) (**Fig. 2A**). *Dio1* up-regulation was accompanied by a profound down-
53 regulation of the stem/progenitor cell marker *Krt-19* (**Fig. 2B,E**). Concomitantly, the
54
55
56
57
58
59
60
61
62
63
64
65

expression of the pro-differentiating transcription factors *Klf9* and *Hnf4a* - strongly decreased in preneoplastic nodules - was up-regulated following T3 treatment (**Fig. 2C and D**). The T3-induced shift towards a differentiated phenotype was further supported by histochemical analysis showing reacquisition of glucose-6-phosphatase (G6Pase) activity, an established marker of differentiated hepatocytes that occurred concomitantly with loss of activity of the preneoplastic marker gamma-glutamyl-transferase (GGT), not expressed by differentiated hepatocytes (**Fig. 2F**).

HCCs are still responsive to T3

Since human HCC is often diagnosed at late stages and treatment options are limited and generally poorly effective, to attribute a clinical relevance to T3 it was important to determine whether not only preneoplastic lesions but also HCCs were responsive to the hormone. Therefore, animals exposed to the R-H model were sacrificed 10 months after DENA. At necropsy, tumors were macroscopically evident in all animals and displayed the typical histological features of HCC, such as irregular edges, with an infiltrating pattern of growth, a marked cellular pleomorphism with mild nuclear atypia, and the normal lobular architecture being replaced by thick trabeculae of neoplastic hepatocytes (**Fig. 3A**). Remaining rats were divided into two groups and fed for one week with either basal diet or T3-supplemented diet (**Fig. S1B**). q-PCR analysis showed that HCCs from untreated rats, similarly to preneoplastic nodules, exhibited diminished *Dio1* mRNA levels that returned to basal values following one-week treatment with T3 (**Fig. 3B**). Restoration of the T3/TR axis in HCCs of T3-treated rats was associated with a strong reduction of *Gstp* and *Krt-19* expression (**Fig. 3C,E**). Notably, while a significant increase of *Klf9* was observed after T3, no such change was found for *Cebpα*, *Cebpβ*, *Foxa2* and *Foxa3* (**Fig. S6**).

T3 reduces HCC number and burden

Having established that HCCs are still responsive to T3 administration, we investigated whether T3 treatment of HCC-bearing animals could interfere with tumor progression. To this aim, 10 months after DENA treatment rats were exposed to 5 cycles of T3-supplemented diet (1 week/every 3 weeks), and sacrificed 3.5 months afterward (**Fig. S2A**). Livers of T3-exposed rats were characterized by very few macroscopic HCCs, while animals fed normal diet displayed large and multiple HCCs (**Fig. 4A,B**). Tumor burden reduction was associated to a significant decrease of liver weight (**Fig. 4C**). Light microscopy examination confirmed a significant reduction of the neoplastic area in T3-treated rats (**Fig. 4D**). Moreover, microscopic observation revealed that lesions with features of adenomas were predominant in the livers of T3-treated animals - with only rare tumors displaying HCC features - while well- or poorly-differentiated HCCs were the vast majority in rats fed basal diet (**Fig. 4E**). This result reinforces the hypothesis that thyroid hormone induces differentiation of neoplastic cells towards a more benign phenotype. Similar to what observed in preneoplastic nodules, restoration of the T3/TR axis, confirmed by the increase of TR β -target genes *Dio1* and *Spot14* expression, was paralleled by *Gstp* and *Krt-19* down-regulation (**Fig. 5A-E**). Concomitantly to the loss of the fetal markers GSTP, KRT-19 and GGT, reacquisition of G6Pase activity was observed in the livers of T3-treated rats (**Fig. 5A, Fig. S7A and Supplementary Table 2**). T3 treatment also induced several HNF4a-positive hepatocyte nuclei (**Fig. 5F**), together with increased *Klf9* mRNA levels and nuclear localization (**Fig. 5G,H**). Interestingly, the expression of *Notch3* and *Hey2* genes, belonging to the Notch signaling pathway involved in the maintenance of stemness and known to display T3-response¹⁸, were down-regulated upon T3 treatment (**Fig. 5I,J**). Altogether, these results demonstrate that T3 massively impairs HCC progression likely promoting differentiation of neoplastic hepatocytes.

Notably, similar to what observed in early preneoplastic lesions, no sign of increased apoptosis was observed in the livers of HCC-bearing animals treated with T3, as determined by Caspase-3 immunostaining (**Fig. S7B**).

An additional rat model was used to test the anti-tumorigenic ability of T3, wherein the clonal expansion of DENA-initiated cells is promoted by a steato-necrogenic environment generated by 4 month-feeding with a choline-devoid, methionine-deficient (CMD) diet (**Fig. S3A**). Ten months after DENA treatment at least one small HCC was observed in all animals. Treatment with 5 cycles of T3-supplemented diet (1 week/every 3 weeks) caused a striking reduction in the number of rats displaying macroscopic tumors (2/8; 25%), when compared to that of animals not exposed to the hormone (4/5; 80%) and in the number of HCC/rat (average: 0.25 vs. 2.4) (**Fig. S7C,D,E**).

T3 inhibits the growth of human HCC cells and their in vivo tumorigenic ability

To directly establish the anti-tumorigenic properties of T3, we evaluated its effect on cell growth and colony forming ability of human HCC cells. While TR β transduction did not significant modify the basal growth ability of either the cell lines (data not shown), treatment with T3 severely impaired the capacity of Mahlavu and HepG2 cells to grow both in adhesion (**Fig. 6A** and **Fig. S8A**) and in the absence of anchorage (**Fig. 6B** and **Fig. S8B**). This effect was more evident in cells transduced with TR β . Notably, the mRNA levels of TR β were similar in both Malhavu and HepG2 cells (**Fig.S8C**). As *in vitro* treatment with T3 significantly induced *KLF9* expression in both Mahlavu and HepG2 cells (**Fig.6C** and **Fig. S8D**), we investigated whether the anti-tumorigenic activity of T3 was linked to KLF9-mediated neoplastic cell differentiation. As shown, *KLF9* silencing significantly impaired the T3 inhibitory effect on anchorage-independent growth (**Fig. 6D** and **Fig. S8E,F**). Moreover, T3 treatment greatly reduced tumor growth of both TR β -

transduced and not transduced Mahlavu cells injected into the posterior flank of nude mice
(Fig. 6E).

TR β /KLF9 axis is affected in a chronic model of rat hepatocarcinogenesis and in human HCC

Evidence supporting the role of TR β /KLF9 axis in HCC development was further investigated in an additional rat model consisting of chronic treatment with DENA (Fig. S3B). Quantitative PCR analysis indeed showed a highly significant down-regulation of *Klf9* and *TR β* in HCCs vs. surrounding livers and a strong positive Pearson correlation between the two genes (Fig. S9A).

To investigate whether a similar correlation exists also in human HCC – and thus endowed with translational value - *KLF9* and *TR β* mRNA levels were determined in a cohort of 45 patients subjected to HCC resection (study population characteristics are described in Supplementary Table 1). Similarly to what observed in rats, human HCCs showed *TR β* and *KLF9* down-regulation in 66% and 60% of human HCCs, respectively, when compared to matched non-cancerous cirrhotic tissues (Fig. S9C,D, left panels). Importantly, a significantly positive correlation between *KLF9* and *TR β* levels was observed (Fig. S9C, right panels). Notably, in both rat and human HCCs we also found a highly significant positive correlation between *TR β* and *KLF9*, and between *HNF4a* and *KLF9* (Fig. S9A-D, right panels).

The anti-tumorigenic effect of T3 is long-lasting and is maintained upon hormone removal

To investigate whether inhibition of HCC progression observed in T3-fed rats is a reversible process depending on the presence of exogenous T3 or it is long-standing, one further group of animals was switched back to basal diet following the 5th cycle with T3-

1 supplemented diet and sacrificed 1 month afterward (**See Fig. S2B**). The results showed
2 that the livers of rats exposed to the hormone were smaller than those of untreated
3 animals and displayed very few macroscopic tumors even after T3 withdrawal (**Fig. 7A**).
4 Light microscopy analysis showed that the average neoplastic area remained significantly
5 reduced in T3-treated animals (**Fig. 7B**). Intriguingly, the T3/TR axis was still partially
6 restored compared to untreated animals, as evidenced by the significantly higher
7 expression of *Dio1* and *Spot14*, even 1 month after T3 withdrawal (**Fig. 7C,D**). Of note, the
8 levels of the neoplastic marker *Krt-19* did not significantly increase following T3 removal,
9 but maintained expression levels similar to rats killed immediately after the 5th cycle and
10 remained down-regulated when compared to T3-untreated rats (**Fig. 7E**).
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 ***T3-induced metabolic rewiring precedes preneoplastic nodules regression***

27 Recent evidence supports a link between metabolism and cell differentiation²¹⁻²³. Based on
28 our previous findings that aggressive preneoplastic lesions and HCCs are characterized by
29 a rewiring of cellular metabolism towards an enhanced glycolytic phenotype (i.e.
30 Warburg)²⁴, we investigated whether the T3-pro-differentiative effect was associated to a
31 rerouting of metabolites from a Warburg metabolism to oxidative phosphorylation
32 (OXPHOS).
33
34
35
36
37
38
39
40
41
42
43

44 We first analyzed the expression profile of the 16 metabolic genes involved in glycolysis,
45 significantly altered in preneoplastic lesions in the array described in Fig. 1A.
46 Unsupervised hierarchical cluster analysis stratified rat lesions into two major clusters: 1)
47 preneoplastic KRT-19+ lesions, and 2) normal liver and preneoplastic KRT-19+ lesions
48 exposed to T3 for 2 or 4 days (**Fig. 8A**). Interestingly, T3 treatment severely affected the
49 expression of metabolic genes as early as 2 days after treatment, a time when no major
50 effect in the global expression profile was observed (**Fig. 1A**). The most marked T3-
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

induced changes were observed in genes belonging to the Pentose Phosphate Pathway (PPP). Indeed, the expression levels of Glucose-6-phosphate dehydrogenase (*G6pd*, the rate-limiting enzyme of the oxidative branch of the PPP), Phosphogluconate dehydrogenase (*Pgd*) and Transaldolase1 (*Taldo1*) were significantly down-regulated by T3 (**Fig. 8A**).

Along with diversion of glycolytic metabolites into the PPP, mitochondrial respiration is impaired in preneoplastic lesions²⁴. Crucially, T3 administration rapidly restored the activity of Succinate Dehydrogenase (SDH), an indicator of mitochondrial functionality, hence impacting the metabolic phenotype of preneoplastic lesions (**Fig. 8B**).

T3 administration reverts HCC metabolic profile

Next, we assessed if the inhibitory effect of T3 on HCC progression is accompanied by a reversion of the tumor metabolic profiles. One-week T3 treatment of HCC bearing rats (10 months after DENA) rescued normal glycolytic activity, as revealed by hexokinase 2 (*Hk2*) and glucose transporter-1 (*Glut1*) decreased expression (**Fig. S10A**). Similar to what observed in preneoplastic nodules, also in these tumors T3 strongly down-regulated the expression and activity of *G6pd* (**Fig. S10B**), *Taldo1* and Transketolase (*Tkt*) levels (**Fig. S10C**).

Based on the finding that G6PD and Taldo1 are targets of the transcription factor Nrf2, PPP activation has been proposed as one of the mechanisms by which deregulation of the Nrf2/Keap1 signaling promotes tumorigenesis²⁷. Since T3 strongly decreased *G6pd*, *Taldo1* and *Tkt* expression (**Fig. 8D**), we investigated whether thyroid hormone could impact the Nrf2-Keap1 pathway. As shown in **Fig. S11**, while NRF2/KEAP1 pathway was strongly activated in HCCs, after 5 cycles of T3 regimen we observed a strong decrease of

the mRNA (**Fig. S11A**) and protein levels (**Fig. S11B**) of Nqo1, the best known Nrf2 target gene, proving NRF2 pathway inhibition.

Enzymatic activity assays displayed increased activity of complex I and II of the respiratory chain in liver tissues belonging to the hormone-treated group (**Fig. S10D**). These results are in line with a previous study reporting that reduction of glycolysis due to *HK2* knock-down in hepatoma cell lines led to a compensatory up-regulation of OXPHOS²⁵.

T3-induced changes in metabolic genes were even more pronounced following 5 cycles of feeding T3-supplemented diet (**Fig. 8C,D**). Indeed, we observed a clear switch from high *Hk2* expression to that of glucokinase (*Gck*), the enzyme that, in normal hepatocytes, catalyzes the first committed step in glucose metabolism²⁶. This switch was accompanied by *Glut1* and *Mct4* down-regulation (**Fig.8C**). A similar effect on metabolic genes was observed in HepG2 cells treated with T3 (**Fig. S12A**). Five cycles of T3 diet also reverted the enhanced expression of *Taldo1*, *Tkt* and *G6pd* usually associated to HCC (**Fig. 8D**). G6PD activity was also significantly decreased by T3 (**Fig. 8D**). T3 ability to interfere with PPP activation was also demonstrated in HepG2 and Mahlavu cells, as shown by decreased CO₂ production from glucose radiolabeled in position 1 (CO₂ derived from both OXPHOS and PPP) subtracting that originated from glucose radiolabeled in position 6 (CO₂ exclusively derived from OXPHOS) (**Fig. 8E and S12B**). These findings are further reinforced by mass spectrometry analysis showing a significant reduction of ribose-5-phosphate (i.e. the final product of the oxidative branch of the PPP) in tumor tissue derived from HCC-bearing rats undergoing T3 treatment (**Fig. S12C**). In agreement with the results shown in **Fig. S12C**, enzymatic activity assays performed on livers of rats exposed to 5 cycles of T3 exhibited increased activity of complex I and II of the respiratory chain (**Fig. 8F**). These data were further confirmed by histochemical analysis of serial frozen sections showing reactivation of SDH activity after T3 treatment (**Fig. S13**). Interestingly, the reduced levels of R5P of the T3 treated samples are accompanied by a significant

increase in phosphoenol pyruvate (PEP) and pyruvate, metabolites that can fuel the TCA cycle, assayed using GC-MS. Indeed, citrate and malate levels are increased and can be considered as a readout of an enhanced TCA cycle **(Fig. S12C)**.

Discussion

The most important findings achieved in this study are: 1) fully developed HCCs are responsive to T3, 2) repeated cycles of T3 to HCC-bearing rats strongly impair HCC progression, 3) the anti-tumorigenic effect of T3 is durable, lasting also after T3 removal, 4) re-differentiation and metabolic switch from glycolysis to OXPHOS precede early lesions regression and impair HCC progression, 5) the T3/TR axis is altered in human HCCs.

TH/TRs are involved in differentiation and metamorphosis²⁸ and T3 accelerates differentiation of oval/liver progenitor cells to hepatocytes, leading to loss of oval cell specific markers and acquisition of a mature hepatocyte phenotype²⁹.

In the RH model used in the present study, the biochemical phenotype of preneoplastic nodules resembles that of fetal hepatocytes, as these lesions lack the expression of enzymes normally present in differentiated hepatocytes, while exhibit high levels of proteins poorly expressed/absent in fully differentiated hepatocytes³⁰. Here, we demonstrate that T3 exerts its effects on preneoplastic nodules and HCCs by inducing genes responsible for acquisition/maintenance of hepatocyte differentiation, such as *Klf9* and *Hnf4a*, and by inhibiting genes expressed in less-differentiated hepatocytes, such as *Krt-19*, *Gstp*, *Ggt*. Our data also imply that the TR/KLF9 network is involved in the re-activation of the differentiation program. The Sp1/KLF transcription factor family plays different roles in cellular growth, development, differentiation and inflammation^{18,20,31}. In particular, *Klf9* expression greatly influences cell differentiation processes. Recently, Cvaro

1 *et al.*²⁰ showed that TRs cooperate with KLF9 to regulate hepatocyte differentiation and
2 TRs activation leads to KLF9 induction in transformed and non-transformed liver cells, and
3
4 in stem cells. *KLF9* was down-regulated in human HCCs while KLF9 transduction in HCC
5
6 cell lines inhibited proliferation and tumorigenesis³². Remarkably, we observed a strong
7
8 decrease of *Klf9* mRNA levels in preneoplastic lesions and HCCs, paralleled by reduced
9
10 TR β expression, and its significant up-regulation following T3 treatment. These data were
11
12 confirmed also in an additional model of rat hepatocarcinogenesis and in human HCCs.
13
14 The finding that T3 impaired growth of human hepatocarcinoma cell lines and that this
15
16 effect was partially reverted upon *KLF9* silencing supports a role of the TR/KLF9 axis in
17
18 the antitumoral effect of T3.
19
20
21
22
23

24 Interestingly, in the model of HCC+T3 administration and T3 withdrawal we observed that
25
26 the antitumoral effects were maintained one month after T3 withdrawal. We hypothesize
27
28 that restoration of the T3/TR axis, persisting even at 1 month after T3 withdrawal – as
29
30 evaluated by the increased expression of Dio1 and Spot14 – might in part explain the long-
31
32 lasting activity of thyroid hormone.
33
34
35

36 Another important observation stemming from this study is that a metabolic switch from
37
38 glycolysis to oxidative-dependent metabolism is an early event in the anti-tumorigenic
39
40 effect exerted by T3. This is in line with the notion that differentiation requires a
41
42 fundamental shift in the metabolic landscape of the cell³³. Unlike normal cells, most
43
44 neoplastic cells undergo an important metabolic shift, known as Warburg effect, in which
45
46 glucose utilization is favored and oxidative phosphorylation is downregulated, even when
47
48 oxygen availability is plentiful³⁴. In human HCCs Nwosu *et al.* found more than 600
49
50 consistently altered metabolic genes³⁵. Moreover, in the R-H model, metabolic
51
52 reprogramming is a feature observed from very early stages that persists up to fully
53
54 developed HCC, suggesting its critical role in HCC onset and progression. Concerning T3,
55
56 several reports have described its effect on cancer cell metabolic behavior. Indeed, T3
57
58
59
60
61
62
63
64
65

1 sensitized mitochondrial metabolism in triple-negative breast cancer cells displaying
2 marked Warburg effect³⁶. In addition, T3 was shown to increase mitochondrial function and
3
4 respiration in HCC cells^{37,38}. In our study, the most marked T3-induced changes affected
5
6 PPP, in particular G6PD, the limiting enzyme of the PPP oxidative branch^{39,40}. G6PD
7
8 expression was completely abolished after T3 treatment, both in nodules and in HCCs,
9
10 and remained low after T3 removal. Notably, in human HCC G6PD expression is up-
11
12 regulated and associated with high tumor grade, metastasis and poor overall survival²⁴.
13
14 Our findings demonstrate that T3 acts as a potent anti-tumoral agent and are in line with
15
16 other reports suggesting that T3 administration interferes with HCC development^{38,41}. In
17
18 fact, T3 suppressed HCC onset in DENA-treated mice via activation of mitophagy³⁷ and in
19
20 HBV-encoded X protein-induced hepatocarcinogenesis³⁸.
21
22 Collectively, these findings shed light on the possibility of targeting the T3/TR axis in HCC
23
24 therapy. Unfortunately, T3-based therapies often result in undesired side effects,
25
26 particularly cardiac dysfunctions⁴², which hamper their clinical use. Nonetheless, new
27
28 thyroid hormone analogs devoid of the cardiac toxic effects of thyroid hormone are now
29
30 available and worth to be tested in clinical trials.
31
32
33
34
35
36
37
38
39

40 **ACKNOWLEDGEMENTS**

41 We thank Dr. VP Leoni and Dr. M. Serra for their valuable technical support.
42
43
44

45 **CTAT**

46 CTAT is supplied as Supplementary CTAT Table.
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

REFERENCES

- [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68:394-424.
- [2] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, *et al.* SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med.* 2008 24;359:378-90.
- [3] Cheng SY, Leonard JL & Davis PJ. Molecular aspects of thyroid hormone actions. *Endocrine Reviews* 2010;31:139–170.
- [4] Brent GA. The molecular basis of thyroid hormone action. *N Engl J Med* 1994;331:847-53.
- [5] **Davis PJ, Goglia F, Leonard JL.** Nongenomic actions of thyroid hormone. *Nat Rev Endocrinol.* 2016;12:111-21.
- [6] Lazar MA. Thyroid hormone receptors: multiple forms, multiple possibilities. *Endocr Rev.* 1993;14:184-9.
- [7] Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, *et al.* Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. *Hepatology* 2009;49:1563-70.
- [8] Reddy A, Dash C, Leerapun A, Mettler TA, Stadheim LM, Lazaridis KN, *et al.* Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. *Clin Gastroenterol Hepatol.* 2007;5:118-23.
- [9] Cable EE, Finn PD, Stebbins JW, Hou J, Ito BR, van Poelje PD, *et al.* Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. *Hepatology* 2009;49:407-17.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [10] **Frau C, Loi R**, Petrelli A, Perra A, Menegon S, Kowalik MA, *et al.* Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats. *Hepatology* 2015;61:249-59.
- [11] Aranda A, Martínez-Iglesias O, Ruiz-Llorente L, García-Carpizo V, Zambrano A. Thyroid receptor: roles in cancer. *Trends Endocrinol Metab.* 2009;20:318-24.
- [12] **Liao CH, Yeh CT**, Huang YH, Wu SM, Chi HC, Tsai MM, *et al.* Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells. *Hepatology* 2012;55:910–920.
- [13] **Angioni MM, Bellofatto K**, Merlin S, Menegon S, Perra A, Petrelli A, *et al.* A long term, non tumorigenic rat hepatocyte cell line and its malignant counterpart, as tools to study hepatocarcinogenesis. *Oncotarget*, 2017; 8:15716-15731
- [14] **Petrelli A, Perra A, Cora D**, Sulas P, Menegon S, Manca C, *et al.* MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). *Hepatology* 2014;59:228-41.
- [15] Sebastián C, Serra M, Yeramian A, Serrat N, Lloberas J, Celada A. Deacetylase activity is required for STAT5-dependent GM-CSF functional activity in macrophages and differentiation to dendritic cells. *J Immunol.* 2008;180:5898-906.
- [16] Ledda-Columbano GM, Perra A, Loi R, Shinozuka H, Columbano A. Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. *Cancer Res.* 2000;60:603-9.
- [17] Costa RH, Kalinichenko VV, Holterman AX, Wang X. Transcription factors in liver development, differentiation, and regeneration. *Hepatology* 2003;38:1331-1347.
- [18] Denver RJ, Williamson KE. Identification of a thyroid hormone response element in the mouse Kruppel-like factor 9 gene to explain its postnatal expression in the brain. *Endocrinology.* 2009;150:3935-43.

- [19] Cui A, Fan H, Zhang Y, Zhang Y, Niu D, Liu S, et al. Dexamethasone-induced Krüppel-like factor 9 expression promotes hepatic gluconeogenesis and hyperglycemia. *J Clin Invest*. 2019;129:2266-2278
- [20] Cvaro A, Devito L, Milton FA, Noli L, Zhang A, Filippi C, et al. A thyroid hormone receptor/KLF9 axis in human hepatocytes and pluripotent stem cells. *Stem Cells*. 2015;33:416-28.
- [21] **Bracha AL, Ramanathan A**, Huang S, Ingber DE, Schreiber SL. Carbon metabolism-mediated myogenic differentiation. *Nat Chem Biol*. 2010;6:202-204.
- [22] White KP, Hurban P, Watanabe T, Hogness DS. Coordination of Drosophila metamorphosis by two ecdysone-induced nuclear receptors. *Science* 1997;276:114-117.
- [23] McGraw TE, Mittal V. Stem cells: Metabolism regulates differentiation. *Nat Chem Biol*. 2010;6:176-177.
- [24] **Kowalik MA, Guzzo G, Morandi A**, Perra A, Menegon S, Masgras I, et al. Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. *Oncotarget* 2016;7:32375-93.
- [25] DeWaal D, Nogueira V, Terry AR, Patra KC, Jeon SM, Guzman G, et al. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. *Nat Commun*. 2018;9:446.
- [26] Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. *J Exp Biol*. 2003;206:2049-57.
- [27] Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. *Cancer Cell*. 2012; 22:66-79.
- [28] Yen PM. Physiological and molecular basis of thyroid hormone action. *Physiol Rev*. 2001;81:1097-142.

- [29] László V, Dezso K, Baghy K, Papp V, Kovalszky I, Sáfrány G, *et al.* Triiodothyronine accelerates differentiation of rat liver progenitor cells into hepatocytes. *Histochem Cell Biol.* 2008;130:1005-14.
- [30] Roomi MW, Ho RK, Sarma DS, Farber E. A common biochemical pattern in preneoplastic hepatocyte nodules generated in four different models in the rat. *Cancer Res.* 1985;45:564-71.
- [31] Cao Z, **Sun X, Icli B, Wara AK**, Feinberg MW. Role of Kruppel-like factors in leukocyte development, function, and disease. *Blood* 2010;116:4404-14.
- [32] Sun J, Wang B, Liu Y, Zhang L, Ma A, Yang Z, *et al.* Transcription factor KLF9 suppresses the growth of hepatocellular carcinoma cells in vivo and positively regulates p53 expression. *Cancer Lett.* 2014;355:25-33
- [33] Agathocleous M, Harris WA. Metabolism in physiological cell proliferation and differentiation. *Trends Cell Biol.* 2013;23:484-92.
- [34] Warburg O. On the origin of cancer cells. *Science* 1956;123:309-314.
- [35] Nwosu ZC, Megger DA, Hammad S, Sitek B, Roessler S, Ebert MP, *et al.* Identification of the Consistently Altered Metabolic Targets in Human Hepatocellular Carcinoma. *Cell Mol Gastroenterol Hepatol.* 2017;4:303-323.e1.
- [36] Suhane S, Ramanujan VK. Thyroid hormone differentially modulates Warburg phenotype in breast cancer cells. *Biochem Biophys Res Commun.* 2011;414:73–8.
- [37] Sinha RA, Singh BK, Zhou J, Wu Y, Farah BL, Ohba K, *et al.* Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling. *Autophagy* 2015;11:1341–57.
- [38] Chi H-C, Chen S-L, Lin S-L, Tsai C-Y, Chuang W-Y, Lin Y-H, *et al.* Thyroid hormone protects hepatocytes from HBx-induced carcinogenesis by enhancing mitochondrial turnover. *Oncogene* 2017;36:5274–84.

- [39] Patra KC and Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014;39:347-354.
- [40] Kowalik MA, Columbano A, Perra A. Emerging Role of the Pentose Phosphate Pathway in Hepatocellular Carcinoma. Front Oncol. 2017;7:87.
- [41] Chi H-C, Chen S-L, Tsai C-Y, Chuang W-Y, Huang Y-H, Tsai M-M, et al. Thyroid hormone suppresses hepatocarcinogenesis via DAPK2 and SQSTM1-dependent selective autophagy. Autophagy. 2016;12:2271–85.
- [42] Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501-9.

FIGURE LEGENDS

Fig. 1. T3 modifies the global gene expression profile of preneoplastic lesions. (A) Hierarchical clustering of 869 genes in normal liver (CO), KRT-19-, KRT-19+ preneoplastic lesions, and KRT-19+ lesions treated with T3 for 2 (T3 2d) or 4 days (T3 4d). Each row represents the expression of a gene and each column a sample. Red and green colors represent higher or lower mRNA expression levels (median-centered), respectively. (B) Enriched pathways in 4 days T3-treated vs. untreated KRT-19+ preneoplastic lesions. P values were determined using the Ingenuity scoring system. Threshold $P < 0.05$. Color bars indicate predicted pathway activation (orange), or inhibition (blue). (C) Network visualization of the transcription factors HNF4a, CEBPa and HNF1a. TF → target gene. Red: up-regulated genes; green: down-regulated genes.

Fig. 2. T3 induces the expression of genes involved in hepatocyte differentiation. (A-D) qPCR analysis of *Dio1*, *Krt-19*, *Klf9* and *HNF4a* mRNA in control livers, preneoplastic GSTP/KRT-19+ nodules, with/without 4 days T3 treatment. Gene expression

is reported as fold-change relative to livers from untreated rats. The histogram represents mean values \pm SD of 6/8 nodules/group (3 to 4 rats per group) (ANOVA test). **(E)** GSTP and KRT-19 immunohistochemical staining of preneoplastic nodules of untreated (-T3) or 4 days T3-treated (+T3) animals. **(F)** H&E, GSTP GGT and G6Pase staining of representative preneoplastic lesions of untreated (-T3) or 4 days T3-treated (+T3) animals (X5). NS: not significant. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

Fig. 3. HCCs maintain the ability to respond to T3. **(A)** HCC displaying a marked cellular pleomorphism in a rat exposed to the RH protocol, killed 10 months after DENA (H&E X20). **(B-D)** qPCR analysis of *Dio1*, *Krt-19*, *Klf9* mRNA in control livers (CO), HCC from rats 10 months after DENA administration, fed (HCC+T3) or not (HCC) a T3-supplemented diet for 1 week. For each liver, qRT-PCR analysis was performed on 25 randomly cut sections obtained from different segments (treated or untreated with T3). Gene expression is reported as fold-change relative to livers from controls. The histogram represents mean values \pm SD of 4-6 rats/group. (ANOVA test) **(E)** HCC serial sections in rats treated as before, stained for H&E, GSTP and KRT-19 (X1.25). NS: not significant. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

Fig. 4. T3-induced reduction of HCC number and burden. **(A)** Table showing the number of animals carrying HCCs and of HCCs/rat. **(B)** Livers of rats exposed to the RH protocol and sacrificed 13.5 months after DENA treated (HCC+T3) or not (HCC) with 5 cycles of T3. **(C)** Liver weight of the same rats. Results are expressed as means \pm SD of 15 rats. (t-test) **(D)** Average of liver area occupied by neoplastic hepatocytes. Tumor burden was evaluated in H&E stained histological sections from at least 5 to 10 liver sections/rat. (t-test) **(E)** Poorly-differentiated HCC in a rat not given T3 (HCC) and a more

differentiated HCC with features of adenomas in the liver of a T3-treated animal (HCC+T3) (H&E X20).

Fig. 5. T3 induces hepatocyte differentiation. (A-D) qPCR analysis of *Dio1*, *Spot-14*, *Gstp* and *Krt-19* mRNA in control liver and in the livers of rats killed 13 months after DENA, with/without 5 cycles of T3. For each liver, qRT-PCR analysis was performed on 25 randomly cut sections obtained from different segments (treated or untreated with T3). Gene expression is reported as fold-change relative to livers from untreated rats. The histogram represents mean values \pm SD of 6/8 livers/group. (ANOVA test) **(E)** GSTP and KRT-19 immunohistochemistry of livers from animals treated as described in A (X5). **(F,G)** HNF4a and KLF9 Immunofluorescence of livers of rats treated as in A (X20). **(H-J)** qPCR analysis of *Klf9*, *Notch3* and *Hey2* mRNA in control livers and in the livers of rats treated as in A. The histogram represents mean values \pm SD of 6/8 livers/group. (ANOVA test) NS: not significant; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

Fig. 6. T3 treatment impairs growth and tumorigenic ability of human HCC cells. (A) Growth curve of Mahlavu cells, transduced with TRB or an empty vector (PLVX) and treated (T3) or not (NT) for 6 days with 100nM T3. O.D.= Optical Density at 590 nm. (multiple t-test) **(B)** Anchorage-independent growth of cells described in A. Visible colonies were counted after 15 days. **(C)** qPCR analysis of KLF9 mRNA levels from cells described in A. (multiple t-test) **(D)** Mahlavu cells described in A were stably transduced with a lentiviral KLF9 short hairpin mix (shKLF9) or a control (shSCR) and grown in anchorage-independent conditions. (multiple t-test) **(E)** Tumor growth curves of Mahlavu cells subcutaneously injected in nude mice fed either T3 diet or basal diet until sacrifice (n =6/group). (two-way ANOVA) Histograms show mean +SD of 3 independent experiments. (t-test) * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

Fig. 7. T3 anti-tumorigenic effect persists after hormone withdrawal. (A) Livers of rats treated with 5 cycles of T3-supplemented diet and killed 1 month after the last T3 cycle. **(B)** Average of the liver area occupied by neoplastic hepatocytes. (t-test) **(C-E)** qPCR analysis of *Dio1*, *Spot14*, *Krt-19* mRNAs in the livers of the rats described in A. For each liver, qRT-PCR analysis was performed on 25 randomly cut sections obtained from different segments (treated or untreated with T3). Gene expression is reported as fold-change relative to livers from untreated rats. The histogram represents mean values + SD of 6 rats/group. (t-test and ANOVA) NS: not significant. *P<0.05; *** P<0.001.

Fig. 8. T3 induces metabolic changes which precede preneoplastic lesion regression and impairment of HCC growth. (A) Hierarchical clustering of 16 genes involved in metabolic reprogramming in normal liver (CO), KRT-19+ preneoplastic lesions, and KRT-19+ lesions, treated with T3 for 2 (T3 2d) or 4 days (T3 4d). Each row represents the expression of a gene and each column a sample. Red and green colors represent higher or lower mRNA expression levels (median-centered), respectively. **(B)** Histochemical reaction evaluating SDH activity in preneoplastic lesions untreated (-T3) or T3-treated (+T3) for 4 days (X5); **(C)** qPCR analysis of the glycolytic genes *GCK*, *HK2*, *Glut1* and *MCT4* mRNA levels in the livers of rats killed 13.5 months after DENA, with (HCC+T3) or without (HCC) 5 cycles of T3. Gene expression is reported as fold-change relative to livers from untreated rats. The histogram represents mean values + SD of 6/8 livers/group. (t-test) **(D)** qPCR analysis of *G6pd*, *Taldo1*, *Tkt* performed and reported as in C, and G6PD activity in livers of rats treated as in C. (t-test) **(E)** Radioactive assay using [14C]-glucose labeled in position C1 or in position C6. Radiolabelled glucose was added for the last hour to HepG2 cells that were cultured either in presence or absence of T3 for 72 hours, before subjecting to CO₂ radioactive analysis (see Methods). PPP CO₂

production results from subtracting the radioactive signal derived from [1-¹⁴C]-glucose to
that of [6-¹⁴C]-glucose. (t-test) **(F)** Complex I and Complex II activity in the livers of rats
treated as in C. (t-test) NS: not significant; *P<0.05; **P <0.01.









Figure T3 10.11.pdf




















Highlights:

- **T3 induces a rapid differentiation program in hepatic preneoplastic lesions**
- **Repeated cycles of T3 impair HCC progression**
- **The anti-tumorigenic effect of T3 is long-lasting and is maintained after withdrawal**
- **T3 reverts HCC metabolic profile**
- **The T3/TR β axis is altered in human HCC**